droperidol (Rx)

Brand and Other Names:Inapsine
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

injectable solution

  • 2.5mg/mL

Antiemetic

Initial: No more than 2.5 mg IV/IM; additional doses of 1.25 mg may be given if benefit outweighs potential risk

Delirium (Off-label)

5 mg IM

Renal Impairment

Use caution; safety and efficacy not established

Hepatic Impairment

Use caution; safety and efficacy not established

Other Information

Monitor: EKG, cardiac function

Other Indications & Uses

Prevention of nausea/vomiting during surgery

Off-label: Adjunct to general anesthesia, prevention of CINV, sedation

Dosage Forms & Strengths

injectable solution

  • 2.5mg/mL

Antiemetic

2-12 years: 0.03-0.07 mg/kg IV/IM over 2-5 minutes q4-6hr PRN  

Not to exceed 0.1 mg/kg IV/IM, additional dose (no more than 2.5 mg) may be given ONLY IF benefit outweighs potential risk

Other Information

Monitor: EKG, cardiac function

Antiemetic

Initial: No more than 2.5 mg IV/IM; additional doses of 1.25 mg may be given if benefit outweighs potential risk

Next:

Interactions

Interaction Checker

and droperidol

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (10)

            • amiodarone

              amiodarone and droperidol both increase QTc interval. Contraindicated.

            • amisulpride

              amisulpride, droperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • disopyramide

              disopyramide and droperidol both increase QTc interval. Contraindicated.

            • ibutilide

              droperidol and ibutilide both increase QTc interval. Contraindicated.

            • indapamide

              droperidol and indapamide both increase QTc interval. Contraindicated.

            • pentamidine

              droperidol and pentamidine both increase QTc interval. Contraindicated.

            • pimozide

              droperidol and pimozide both increase QTc interval. Contraindicated.

            • procainamide

              droperidol and procainamide both increase QTc interval. Contraindicated.

            • quinidine

              quinidine and droperidol both increase QTc interval. Contraindicated.

            • sotalol

              droperidol and sotalol both increase QTc interval. Contraindicated.

            Serious - Use Alternative (103)

            • alfuzosin

              alfuzosin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • amisulpride

              amisulpride and droperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • amitriptyline

              amitriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • amoxapine

              amoxapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • apomorphine

              droperidol decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

              apomorphine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • aripiprazole

              aripiprazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • arsenic trioxide

              arsenic trioxide and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether

              artemether and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether/lumefantrine

              droperidol and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

            • atomoxetine

              atomoxetine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • bromocriptine

              droperidol decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

            • cabergoline

              droperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.

            • calcium/magnesium/potassium/sodium oxybates

              droperidol, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

            • ceritinib

              ceritinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • chlorpromazine

              chlorpromazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • clarithromycin

              clarithromycin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • clomipramine

              clomipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • clozapine

              clozapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • degarelix

              degarelix and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • desflurane

              desflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • desipramine

              desipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • deutetrabenazine

              deutetrabenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • dofetilide

              dofetilide and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • donepezil

              donepezil and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • dopamine

              droperidol decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.

            • doxepin

              doxepin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • dronedarone

              dronedarone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • efavirenz

              efavirenz and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • encorafenib

              encorafenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • entrectinib

              droperidol and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.

            • epinephrine

              epinephrine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • epinephrine racemic

              epinephrine racemic and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • eribulin

              eribulin and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.

            • erythromycin base

              droperidol and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin ethylsuccinate

              droperidol and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin lactobionate

              droperidol and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.

            • erythromycin stearate

              droperidol and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.

            • escitalopram

              escitalopram increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.

            • fexinidazole

              fexinidazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.

            • fingolimod

              fingolimod and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • fluconazole

              droperidol and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • fluphenazine

              fluphenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • formoterol

              droperidol and formoterol both increase QTc interval. Avoid or Use Alternate Drug.

            • gemifloxacin

              gemifloxacin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • gilteritinib

              gilteritinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • glasdegib

              droperidol and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

            • granisetron

              granisetron and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • haloperidol

              droperidol and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • hydroxychloroquine sulfate

              hydroxychloroquine sulfate and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • hydroxyzine

              hydroxyzine increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

            • imipramine

              imipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • inotuzumab

              inotuzumab and droperidol both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

            • isoflurane

              isoflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • itraconazole

              itraconazole and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • ivosidenib

              ivosidenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

            • ketoconazole

              droperidol and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • lefamulin

              lefamulin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • levodopa

              droperidol decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

            • levodopa inhaled

              droperidol decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of dopamine D2 receptor antagonists with levodopa inhaled.

            • levoketoconazole

              droperidol and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • lisuride

              droperidol decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.

            • lithium

              lithium and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • lofepramine

              lofepramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • lumefantrine

              droperidol and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.

            • macimorelin

              macimorelin and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

            • maprotiline

              maprotiline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • methyldopa

              droperidol decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.

            • metoclopramide intranasal

              droperidol, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

            • mirtazapine

              mirtazapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • mobocertinib

              mobocertinib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.

            • moxifloxacin

              droperidol and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.

            • nilotinib

              droperidol and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.

            • nortriptyline

              nortriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • octreotide

              droperidol and octreotide both increase QTc interval. Avoid or Use Alternate Drug.

            • octreotide (Antidote)

              droperidol and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.

            • olanzapine

              olanzapine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • ondansetron

              droperidol and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

            • oxaliplatin

              oxaliplatin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • panobinostat

              droperidol and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.

            • perphenazine

              perphenazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • pitolisant

              droperidol and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.

            • pramipexole

              droperidol decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.

            • primaquine

              primaquine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • prochlorperazine

              prochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • promazine

              promazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • promethazine

              promethazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • protriptyline

              protriptyline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • ribociclib

              ribociclib increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug.

            • romidepsin

              droperidol and romidepsin both increase QTc interval. Avoid or Use Alternate Drug.

            • ropeginterferon alfa 2b

              ropeginterferon alfa 2b and droperidol both increase Other (see comment). Avoid or Use Alternate Drug. Narcotics, hypnotics or sedatives can produce additive neuropsychiatric side effects. Avoid use and monitor patients receiving the combination for effects of excessive CNS toxicity.

            • ropinirole

              droperidol decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.

            • saquinavir

              saquinavir increases levels of droperidol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for increased toxicity. Increased risk of QT prolongation and cardiac arrhythmias.

            • sevoflurane

              sevoflurane and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • sodium oxybate

              droperidol, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

            • thioridazine

              thioridazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • trazodone

              trazodone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • trifluoperazine

              trifluoperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • trimipramine

              trimipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.

            • umeclidinium bromide/vilanterol inhaled

              droperidol increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • vandetanib

              droperidol, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.

            • vemurafenib

              vemurafenib and droperidol both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.

            • vilanterol/fluticasone furoate inhaled

              droperidol increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • ziprasidone

              droperidol and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.

            Monitor Closely (270)

            • aclidinium

              aclidinium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • albuterol

              droperidol increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              albuterol and droperidol both increase QTc interval. Use Caution/Monitor.

            • alfentanil

              alfentanil and droperidol both increase sedation. Use Caution/Monitor.

            • alfuzosin

              droperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • alprazolam

              alprazolam and droperidol both increase sedation. Use Caution/Monitor.

            • amifampridine

              droperidol increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

            • amitriptyline

              droperidol and amitriptyline both increase sedation. Use Caution/Monitor.

            • amobarbital

              amobarbital and droperidol both increase sedation. Use Caution/Monitor.

            • amoxapine

              droperidol and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and amoxapine both increase sedation. Use Caution/Monitor.

            • anticholinergic/sedative combos

              anticholinergic/sedative combos decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              anticholinergic/sedative combos decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of anticholinergic/sedative combos by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • apomorphine

              droperidol and apomorphine both increase sedation. Use Caution/Monitor.

            • arformoterol

              droperidol increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              arformoterol and droperidol both increase QTc interval. Use Caution/Monitor.

            • aripiprazole

              aripiprazole and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              aripiprazole and droperidol both increase sedation. Use Caution/Monitor.

            • armodafinil

              droperidol increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • atracurium

              atracurium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atracurium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of atracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • atropine

              atropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of atropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • atropine IV/IM

              droperidol increases effects of atropine IV/IM by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              atropine IV/IM decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              atropine IV/IM decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

            • azelastine

              azelastine and droperidol both increase sedation. Use Caution/Monitor.

            • azithromycin

              azithromycin and droperidol both increase QTc interval. Use Caution/Monitor.

            • baclofen

              baclofen and droperidol both increase sedation. Use Caution/Monitor.

            • bedaquiline

              droperidol and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

            • belladonna alkaloids

              belladonna alkaloids decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              belladonna alkaloids decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of belladonna alkaloids by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • belladonna and opium

              belladonna and opium and droperidol both increase sedation. Use Caution/Monitor.

              belladonna and opium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              belladonna and opium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of belladonna and opium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • benperidol

              benperidol and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              benperidol and droperidol both increase sedation. Use Caution/Monitor.

            • benzphetamine

              droperidol increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • benztropine

              droperidol increases effects of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. .

            • brexanolone

              brexanolone, droperidol. Either increases toxicity of the other by sedation. Use Caution/Monitor.

            • brompheniramine

              brompheniramine and droperidol both increase sedation. Use Caution/Monitor.

            • buprenorphine

              buprenorphine and droperidol both increase sedation. Use Caution/Monitor.

            • buprenorphine buccal

              buprenorphine buccal and droperidol both increase sedation. Use Caution/Monitor.

            • butabarbital

              butabarbital and droperidol both increase sedation. Use Caution/Monitor.

            • butalbital

              butalbital and droperidol both increase sedation. Use Caution/Monitor.

            • butorphanol

              butorphanol and droperidol both increase sedation. Use Caution/Monitor.

            • caffeine

              droperidol increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • carbinoxamine

              carbinoxamine and droperidol both increase sedation. Use Caution/Monitor.

            • carisoprodol

              carisoprodol and droperidol both increase sedation. Use Caution/Monitor.

            • cenobamate

              cenobamate, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor.

            • chloral hydrate

              chloral hydrate and droperidol both increase sedation. Use Caution/Monitor.

            • chlordiazepoxide

              chlordiazepoxide and droperidol both increase sedation. Use Caution/Monitor.

            • chloroquine

              chloroquine increases toxicity of droperidol by QTc interval. Use Caution/Monitor.

            • chlorpheniramine

              chlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.

            • chlorpromazine

              chlorpromazine and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              chlorpromazine and droperidol both increase sedation. Use Caution/Monitor.

            • chlorzoxazone

              chlorzoxazone and droperidol both increase sedation. Use Caution/Monitor.

            • cinnarizine

              cinnarizine and droperidol both increase sedation. Use Caution/Monitor.

            • ciprofloxacin

              ciprofloxacin and droperidol both decrease QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.

            • cisatracurium

              cisatracurium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cisatracurium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • citalopram

              droperidol and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

            • clemastine

              clemastine and droperidol both increase sedation. Use Caution/Monitor.

            • clobazam

              droperidol, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

            • clomipramine

              droperidol and clomipramine both increase sedation. Use Caution/Monitor.

            • clonazepam

              clonazepam and droperidol both increase sedation. Use Caution/Monitor.

            • clonidine

              clonidine, droperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.

            • clorazepate

              clorazepate and droperidol both increase sedation. Use Caution/Monitor.

            • clozapine

              clozapine and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              clozapine and droperidol both increase sedation. Use Caution/Monitor.

            • codeine

              codeine and droperidol both increase sedation. Use Caution/Monitor.

            • crizotinib

              crizotinib and droperidol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.

            • cyclizine

              cyclizine and droperidol both increase sedation. Use Caution/Monitor.

              cyclizine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cyclizine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • cyclobenzaprine

              cyclobenzaprine and droperidol both increase sedation. Use Caution/Monitor.

              droperidol, cyclobenzaprine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of V tach, fibrillation.

              cyclobenzaprine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              cyclobenzaprine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • cyproheptadine

              cyproheptadine and droperidol both increase sedation. Use Caution/Monitor.

            • dantrolene

              dantrolene and droperidol both increase sedation. Use Caution/Monitor.

            • daridorexant

              droperidol and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.

            • darifenacin

              darifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              darifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • dasatinib

              dasatinib and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.

            • desflurane

              desflurane and droperidol both increase sedation. Use Caution/Monitor.

            • desipramine

              droperidol and desipramine both increase sedation. Use Caution/Monitor.

            • dexchlorpheniramine

              dexchlorpheniramine and droperidol both increase sedation. Use Caution/Monitor.

            • dexfenfluramine

              droperidol increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dexmedetomidine

              dexmedetomidine and droperidol both increase sedation. Use Caution/Monitor.

            • dexmethylphenidate

              droperidol increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dextroamphetamine

              droperidol increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dextromoramide

              dextromoramide and droperidol both increase sedation. Use Caution/Monitor.

            • diamorphine

              diamorphine and droperidol both increase sedation. Use Caution/Monitor.

            • diazepam

              diazepam and droperidol both increase sedation. Use Caution/Monitor.

            • dicyclomine

              dicyclomine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              dicyclomine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • diethylpropion

              droperidol increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • difelikefalin

              difelikefalin and droperidol both increase sedation. Use Caution/Monitor.

            • difenoxin hcl

              difenoxin hcl and droperidol both increase sedation. Use Caution/Monitor.

            • dimenhydrinate

              dimenhydrinate and droperidol both increase sedation. Use Caution/Monitor.

            • diphenhydramine

              diphenhydramine and droperidol both increase sedation. Use Caution/Monitor.

              diphenhydramine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              diphenhydramine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • diphenoxylate hcl

              diphenoxylate hcl and droperidol both increase sedation. Use Caution/Monitor.

            • dipipanone

              dipipanone and droperidol both increase sedation. Use Caution/Monitor.

            • dobutamine

              droperidol increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dolasetron

              dolasetron and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.

            • dopamine

              droperidol increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dopexamine

              droperidol increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • dosulepin

              droperidol and dosulepin both increase sedation. Use Caution/Monitor.

            • doxepin

              droperidol and doxepin both increase sedation. Use Caution/Monitor.

            • doxylamine

              doxylamine and droperidol both increase sedation. Use Caution/Monitor.

            • ephedrine

              droperidol increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • epinephrine

              droperidol increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • epinephrine racemic

              droperidol increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • esketamine intranasal

              esketamine intranasal, droperidol. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

            • estazolam

              estazolam and droperidol both increase sedation. Use Caution/Monitor.

            • ethanol

              droperidol and ethanol both increase sedation. Use Caution/Monitor.

            • etomidate

              etomidate and droperidol both increase sedation. Use Caution/Monitor.

            • ezogabine

              ezogabine, droperidol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

            • fenfluramine

              droperidol increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • fesoterodine

              fesoterodine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              fesoterodine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • flavoxate

              flavoxate decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              flavoxate decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • flecainide

              droperidol and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.

            • fluoxetine

              droperidol and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.

            • fluphenazine

              droperidol and fluphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and fluphenazine both increase sedation. Use Caution/Monitor.

            • flurazepam

              flurazepam and droperidol both increase sedation. Use Caution/Monitor.

            • formoterol

              droperidol increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • foscarnet

              droperidol and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.

            • fostemsavir

              droperidol and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

            • gadobenate

              gadobenate and droperidol both increase QTc interval. Use Caution/Monitor.

            • ganaxolone

              droperidol and ganaxolone both increase sedation. Use Caution/Monitor.

            • gemtuzumab

              droperidol and gemtuzumab both increase QTc interval. Use Caution/Monitor.

            • glycopyrrolate

              droperidol increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • glycopyrrolate inhaled

              glycopyrrolate inhaled decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              glycopyrrolate inhaled decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • goserelin

              goserelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

            • guanfacine

              guanfacine, droperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.

            • haloperidol

              droperidol and haloperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and haloperidol both increase sedation. Use Caution/Monitor.

            • henbane

              henbane decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              henbane decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • histrelin

              histrelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

            • homatropine

              homatropine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              homatropine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • hydromorphone

              hydromorphone and droperidol both increase sedation. Use Caution/Monitor.

            • hydroxyzine

              hydroxyzine and droperidol both increase sedation. Use Caution/Monitor.

            • hyoscyamine

              hyoscyamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              hyoscyamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • hyoscyamine spray

              droperidol increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

              hyoscyamine spray decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              hyoscyamine spray decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

            • iloperidone

              droperidol and iloperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              droperidol and iloperidone both increase sedation. Use Caution/Monitor.

            • imipramine

              droperidol and imipramine both increase sedation. Use Caution/Monitor.

            • incobotulinumtoxinA

              droperidol increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • indacaterol, inhaled

              indacaterol, inhaled, droperidol. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

            • ipratropium

              ipratropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              ipratropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • isoproterenol

              droperidol increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • ketotifen, ophthalmic

              droperidol and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

            • lapatinib

              droperidol and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.

            • lasmiditan

              lasmiditan, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

            • lemborexant

              lemborexant, droperidol. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

            • lenvatinib

              droperidol and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

            • leuprolide

              leuprolide increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

            • levalbuterol

              droperidol increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • levofloxacin

              droperidol and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

            • levorphanol

              levorphanol and droperidol both increase sedation. Use Caution/Monitor.

            • lisdexamfetamine

              droperidol increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • lofepramine

              droperidol and lofepramine both increase sedation. Use Caution/Monitor.

            • lofexidine

              droperidol and lofexidine both increase sedation. Use Caution/Monitor.

            • loprazolam

              loprazolam and droperidol both increase sedation. Use Caution/Monitor.

            • lorazepam

              lorazepam and droperidol both increase sedation. Use Caution/Monitor.

            • lormetazepam

              lormetazepam and droperidol both increase sedation. Use Caution/Monitor.

            • loxapine

              droperidol and loxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and loxapine both increase sedation. Use Caution/Monitor.

            • loxapine inhaled

              droperidol and loxapine inhaled both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and loxapine inhaled both increase sedation. Use Caution/Monitor.

            • lurasidone

              lurasidone, droperidol. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for additive CNS effects .

            • maprotiline

              droperidol and maprotiline both increase sedation. Use Caution/Monitor.

            • marijuana

              droperidol and marijuana both increase sedation. Use Caution/Monitor.

            • meclizine

              meclizine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              meclizine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • melatonin

              droperidol and melatonin both increase sedation. Use Caution/Monitor.

            • meperidine

              meperidine and droperidol both increase sedation. Use Caution/Monitor.

            • meprobamate

              droperidol and meprobamate both increase sedation. Use Caution/Monitor.

            • metaproterenol

              droperidol increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • metaxalone

              metaxalone and droperidol both increase sedation. Use Caution/Monitor.

            • methadone

              droperidol and methadone both increase QTc interval. Modify Therapy/Monitor Closely.

              methadone and droperidol both increase sedation. Use Caution/Monitor.

            • methamphetamine

              droperidol increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • methocarbamol

              methocarbamol and droperidol both increase sedation. Use Caution/Monitor.

            • methscopolamine

              methscopolamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              methscopolamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • methylenedioxymethamphetamine

              droperidol increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • metoclopramide

              droperidol and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

            • midazolam

              midazolam and droperidol both increase sedation. Use Caution/Monitor.

            • midazolam intranasal

              midazolam intranasal, droperidol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

            • midodrine

              droperidol increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • mifepristone

              mifepristone, droperidol. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.

            • mirtazapine

              droperidol and mirtazapine both increase sedation. Use Caution/Monitor.

            • modafinil

              droperidol increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • morphine

              morphine and droperidol both increase sedation. Use Caution/Monitor.

            • motherwort

              droperidol and motherwort both increase sedation. Use Caution/Monitor.

            • moxonidine

              droperidol and moxonidine both increase sedation. Use Caution/Monitor.

            • nabilone

              droperidol and nabilone both increase sedation. Use Caution/Monitor.

            • nalbuphine

              nalbuphine and droperidol both increase sedation. Use Caution/Monitor.

            • norepinephrine

              droperidol increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • nortriptyline

              droperidol and nortriptyline both increase sedation. Use Caution/Monitor.

            • ofloxacin

              droperidol and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.

            • olanzapine

              droperidol and olanzapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and olanzapine both increase sedation. Use Caution/Monitor.

            • olodaterol inhaled

              droperidol and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

            • onabotulinumtoxinA

              onabotulinumtoxinA decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              onabotulinumtoxinA decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • opium tincture

              opium tincture and droperidol both increase sedation. Use Caution/Monitor.

            • orphenadrine

              orphenadrine and droperidol both increase sedation. Use Caution/Monitor.

            • osilodrostat

              osilodrostat and droperidol both increase QTc interval. Use Caution/Monitor.

            • osimertinib

              osimertinib and droperidol both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

            • oxaliplatin

              oxaliplatin will increase the level or effect of droperidol by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.

            • oxazepam

              oxazepam and droperidol both increase sedation. Use Caution/Monitor.

            • oxybutynin

              oxybutynin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxybutynin topical

              oxybutynin topical decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin topical decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxybutynin transdermal

              oxybutynin transdermal decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              oxybutynin transdermal decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • oxycodone

              oxycodone and droperidol both increase sedation. Use Caution/Monitor.

            • oxymorphone

              oxymorphone and droperidol both increase sedation. Use Caution/Monitor.

            • ozanimod

              ozanimod and droperidol both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

            • paliperidone

              droperidol and paliperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              droperidol and paliperidone both increase sedation. Use Caution/Monitor.

            • pancuronium

              pancuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              pancuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • papaveretum

              papaveretum and droperidol both increase sedation. Use Caution/Monitor.

            • papaverine

              droperidol and papaverine both increase sedation. Use Caution/Monitor.

            • paroxetine

              droperidol and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.

            • pasireotide

              droperidol and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

            • pazopanib

              droperidol and pazopanib both increase QTc interval. Use Caution/Monitor.

            • pentazocine

              pentazocine and droperidol both increase sedation. Use Caution/Monitor.

            • pentobarbital

              pentobarbital and droperidol both increase sedation. Use Caution/Monitor.

            • perphenazine

              droperidol and perphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and perphenazine both increase sedation. Use Caution/Monitor.

            • phendimetrazine

              droperidol increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • phenobarbital

              phenobarbital and droperidol both increase sedation. Use Caution/Monitor.

            • phentermine

              droperidol increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • phenylephrine

              droperidol increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • phenylephrine PO

              droperidol increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

            • pholcodine

              droperidol and pholcodine both increase sedation. Use Caution/Monitor.

            • pimozide

              droperidol and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and pimozide both increase sedation. Use Caution/Monitor.

            • pirbuterol

              droperidol increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • posaconazole

              droperidol and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.

            • pralidoxime

              pralidoxime decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              pralidoxime decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • primidone

              primidone and droperidol both increase sedation. Use Caution/Monitor.

            • prochlorperazine

              droperidol and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and prochlorperazine both increase sedation. Use Caution/Monitor.

            • promethazine

              droperidol and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              promethazine and droperidol both increase sedation. Use Caution/Monitor.

            • propantheline

              propantheline decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              propantheline decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • propofol

              propofol and droperidol both increase sedation. Use Caution/Monitor.

            • propylhexedrine

              droperidol increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • protriptyline

              droperidol and protriptyline both increase sedation. Use Caution/Monitor.

            • quazepam

              quazepam and droperidol both increase sedation. Use Caution/Monitor.

            • quetiapine

              droperidol and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and quetiapine both increase sedation. Use Caution/Monitor.

              quetiapine, droperidol. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.

            • quinine

              droperidol and quinine both increase QTc interval. Use Caution/Monitor.

            • ramelteon

              droperidol and ramelteon both increase sedation. Use Caution/Monitor.

            • ranolazine

              droperidol and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.

            • rapacuronium

              rapacuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              rapacuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • rilpivirine

              rilpivirine increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.

            • rimabotulinumtoxinB

              droperidol increases effects of rimabotulinumtoxinB by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • risperidone

              droperidol and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.

              droperidol and risperidone both increase sedation. Use Caution/Monitor.

            • rocuronium

              rocuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              rocuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • salmeterol

              droperidol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • scopolamine

              scopolamine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              scopolamine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • scullcap

              droperidol and scullcap both increase sedation. Use Caution/Monitor.

            • secobarbital

              secobarbital and droperidol both increase sedation. Use Caution/Monitor.

            • selpercatinib

              selpercatinib increases toxicity of droperidol by QTc interval. Use Caution/Monitor.

            • sevoflurane

              sevoflurane and droperidol both increase sedation. Use Caution/Monitor.

            • shepherd's purse

              droperidol and shepherd's purse both increase sedation. Use Caution/Monitor.

            • sodium sulfate/?magnesium sulfate/potassium chloride

              sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .

            • sodium sulfate/potassium sulfate/magnesium sulfate

              sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .

            • solifenacin

              solifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              solifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • sorafenib

              sorafenib and droperidol both increase QTc interval. Use Caution/Monitor.

            • stiripentol

              stiripentol, droperidol. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

            • sufentanil

              sufentanil and droperidol both increase sedation. Use Caution/Monitor.

            • sulfamethoxazole

              sulfamethoxazole and droperidol both increase QTc interval. Modify Therapy/Monitor Closely.

            • tapentadol

              tapentadol and droperidol both increase sedation. Use Caution/Monitor.

            • telavancin

              droperidol and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.

            • temazepam

              temazepam and droperidol both increase sedation. Use Caution/Monitor.

            • terbutaline

              droperidol increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • tetrabenazine

              droperidol and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.

            • thioridazine

              droperidol and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and thioridazine both increase sedation. Use Caution/Monitor.

            • thiothixene

              droperidol and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and thiothixene both increase sedation. Use Caution/Monitor.

            • tiotropium

              tiotropium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              tiotropium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • tolterodine

              tolterodine decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              tolterodine decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • topiramate

              droperidol and topiramate both increase sedation. Modify Therapy/Monitor Closely.

            • tramadol

              tramadol and droperidol both increase sedation. Use Caution/Monitor.

            • trazodone

              droperidol and trazodone both increase sedation. Use Caution/Monitor.

            • triazolam

              triazolam and droperidol both increase sedation. Use Caution/Monitor.

            • triclofos

              triclofos and droperidol both increase sedation. Use Caution/Monitor.

            • trifluoperazine

              droperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and trifluoperazine both increase sedation. Use Caution/Monitor.

            • trihexyphenidyl

              droperidol increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.

            • trimethoprim

              droperidol and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.

            • trimipramine

              droperidol and trimipramine both increase sedation. Use Caution/Monitor.

            • triprolidine

              triprolidine and droperidol both increase sedation. Use Caution/Monitor.

            • triptorelin

              triptorelin increases toxicity of droperidol by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

            • tropisetron

              droperidol and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.

            • trospium chloride

              trospium chloride decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              trospium chloride decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • vecuronium

              vecuronium decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

              vecuronium decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

              droperidol increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

            • venlafaxine

              droperidol and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.

            • voclosporin

              voclosporin, droperidol. Either increases effects of the other by QTc interval. Use Caution/Monitor.

            • voriconazole

              droperidol and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.

            • xylometazoline

              droperidol increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • yohimbine

              droperidol increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • ziconotide

              droperidol and ziconotide both increase sedation. Use Caution/Monitor.

            • ziprasidone

              droperidol and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and ziprasidone both increase sedation. Use Caution/Monitor.

            • zotepine

              droperidol and zotepine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.

              droperidol and zotepine both increase sedation. Use Caution/Monitor.

            Minor (5)

            • brimonidine

              brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

            • chasteberry

              chasteberry decreases effects of droperidol by pharmacodynamic antagonism. Minor/Significance Unknown. (Theoretical interaction).

            • ethanol

              ethanol, droperidol. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.

            • eucalyptus

              droperidol and eucalyptus both increase sedation. Minor/Significance Unknown.

            • sage

              droperidol and sage both increase sedation. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            >10%

            Restlessness

            Anxiety

            Extrapyramidal Symptoms

            Dystonic reactions

            Pseudoparkinsonian signs and symptoms

            Tardive dyskinesia

            Seizure

            Altered central temperature regulation

            Sedation

            Drowsiness

            Prolonged QT interval (dose dependent)

            Swelling of breasts

            Weight gain

            Constipation

            1-10%

            Hallucinations

            Persistent tardive dyskinesia

            Akathisia

            Orthostatic hypotension

            Tachycardia

            ECG: abnormal T waves

            Hypertension

            Nausea

            Vomiting

            Dysuria

            Frequency Not Defined

            Serious, potentially fatal cardiac effects: prolonged QT interval, torsades de pointes, cardiac arrest, ventricular tachycardia

            Previous
            Next:

            Warnings

            Black Box Warnings

            Cases of QT prolongation and/or torsade de pointes reported in patients receiving therapy at doses at or below recommended doses; some cases have occurred in patients with no known risk factors for QT prolongation and some cases have been fatal

            Due potential for serious proarrhythmic effects and death, this drug should be reserved for use in treatment of patients who fail to show an acceptable response to other adequate treatments, either because of insufficient effectiveness or inability to achieve an effective dose due to intolerable adverse effects from those drugs

            Cases of QT prolongation and serious arrhythmias (eg, torsade de pointes) reported in patients treated with this drug; based on these reports, all patients should undergo a 12-lead ECG prior to initiation of treatment to determine if a prolonged QT interval (eg, QTc > 440 msec for males or 450 msec for females) is present; if there is prolonged QT interval, this drug should not be administered

            For patients in whom potential benefit of treatment is felt to outweigh risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2 to 3 hr after completing treatment to monitor for arrhythmias

            This drug is contraindicated in patients with known or suspected QT prolongation, including patients with congenital long QT syndrome

            This drug should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (eg, congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval)

            Other risk factors may include age >65 years, alcohol abuse, and use of agents such as benzodiazepines, volatile anesthetics, and IV opiates; treatment should be initiated at a low dose and adjusted upward, with caution, as needed to achieve desired effect

            Contraindications

            Known or suspected QT prolongation (eg, QTc interval greater than 440 msec for males or 450 msec for females); including patients with congenital long QT syndrome

            Any use other than for treatment of perioperative nausea and vomiting in patients for whom other treatments are ineffective or inappropriate

            Cautions

            Cases of QT prolongation and serious arrhythmias (eg, torsade de pointes, ventricular arrhythmias, cardiac arrest, and death) reported during post-marketing treatment with this drug; some cases have occurred in patients with no known risk factors and at doses at or below recommended doses; there has been at least one case of nonfatal torsade de pointes confirmed by rechallenge

            All patients should undergo a 12-lead ECG prior to administration of this drug to determine if a prolonged QT interval (eg, QTc > 440 msec for males or 450 msec for females) is present; if there is a prolonged QT interval, this drug should not be administered; for patients in whom the potential benefit of the treatment is felt to outweigh risks of potentially serious arrhythmias, ECG monitoring should be performed prior to treatment and continued for 2-3 hours after completing treatment to monitor for arrhythmias; vital signs and ECG should be monitored routinely

            Fluids and other countermeasures to manage hypotension should be readily available

            As with other CNS depressant drugs, patients who have received this drug should have appropriate surveillance

            Recommended that opioids, when required, initially be used in reduced doses

            As with other neuroleptic agents, very rare reports of neuroleptic malignant syndrome (altered consciousness, muscle rigidity, and autonomic instability) reported in patients who have received this drug

            Since it may be difficult to distinguish neuroleptic malignant syndrome from malignant hyperpyrexia in the perioperative period, consider prompt treatment with dantrolene if increases in temperature, heart rate, or carbon dioxide production occur

            Appropriately reduce initial dose of this drug in the elderly, debilitated, and other poor-risk patients; effect of initial dose should be considered in determining incremental doses

            Since this drug may decrease pulmonary arterial pressure, this fact should be considered by those who conduct diagnostic or surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient

            When the EEG is used for postoperative monitoring, it may be found that the EEG pattern returns to normal slowly

            Inapsine should be administered with caution to patients with liver and kidney dysfunction because of the importance of these organs in the metabolism and excretion of drugs

            In patients with diagnosed/suspected pheochromocytoma, severe hypertension and tachycardia reported after administration of therapy

            Hypotension

            • Certain forms of conduction anesthesia, such as spinal anesthesia and some peridural anesthetics, can alter respiration by blocking intercostal nerves and can cause peripheral vasodilatation and hypotension because of sympathetic blockade
            • Through other mechanisms, this drug can also alter circulation; as such, when used to supplement these forms of anesthesia, the anesthetist should be familiar with the physiological alterations involved, and be prepared to manage them in the patients elected for these forms of anesthesia
            • If hypotension occurs, the possibility of hypovolemia should be considered and managed with appropriate parenteral fluid therapy; repositioning the patient to improve venous return to the heart should be considered when operative conditions permit
            • It should be noted that in spinal and peridural anesthesia, tilting the patient into a head-down position may result in a higher level of anesthesia than is desirable, as well as impair venous return to the heart
            • Care should be exercised in moving and positioning of patients because of a possibility of orthostatic hypotension; if volume expansion with fluids plus these other countermeasures do not correct the hypotension, then the administration of pressor agents other than epinephrine should be considered
            • Epinephrine may paradoxically decrease the blood pressure in patients treated with Inapsine due to the alpha-adrenergic blocking action of Inapsine

            Risk factors prolonging QT interval

            • Therapy should be administered with extreme caution in presence of risk factors for development of prolonged QT syndrome as listed below
            • Clinically significant bradycardia (less than 50 bpm
            • Clinically significant cardiac disease
            • Treatment with Class I and Class III antiarrhythmics
            • Treatment with monoamine oxidase inhibitors (MAOI's)
            • Concomitant treatment with other drug products known to prolong the QT interval
            • Electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (eg, diuretics) that may cause electrolyte imbalance
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            There are no adequate and well-controlled studies in pregnant women. Inapsine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

            Animal data

            • Administered intravenously has been shown to cause a slight increase in mortality of the newborn rat at 4.4 times the upper human dose; at 44 times the upper human dose, mortality rate was comparable to that for control animals
            • Following intramuscular administration, increased mortality of the offspring at 1.8 times the upper human dose is attributed to CNS depression in the dams who neglected to remove placentae from their offspring; this drug has not been shown to be teratogenic in animals

            Lactation

            Not known whether this drug is excreted in human milk; because many drugs are excreted in human milk, caution should be exercised when Inapsine is administered to a nursing mother

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Antiemesis: dopamine receptor blockade in brain, predominantly dopamine-2 receptor & when reuptake is prevented, a strong antidopaminergic, antiserotonic response occurs

            Droperidol reduced motor activity, anxiety, and causes sedation; also possesses adrenergic-blocking, antifibrillatory, antihistaminic, & anticonvulsive properties

            Pharmacotherapy

            Half-Life elimination: 2 hr (parent drug), 8-12 hr (metabolites)

            Onset: 3-10 min

            Duration: 2-4 hr, may persist up to12 hr

            Peak Response Time: 10-30 min

            Peak Plasma Time: 60 min (IM)

            Protein Bound: extensive

            Metabolism: extensively in the liver

            Metabolites: [Benzimidazolone, p-Fluorophenylacetic acid, p-Hydroxypiperidine] (inactive)

            Vd: 2 L/kg (Adults); 0.58 L/kg (Children)

            Excretion: Urine (75%); feces (22%)

            Previous
            Next:

            Administration

            IV Incompatibilities

            Syringe: fluorouracil, furosemide, heparin, leucovorin, methotrexate, ondansetron, pentobarbital

            Y-site: allopurinol, amphotericin B cholesteryl SO4, cefepime, fluorouracil, fascarnet, furosemide, heparin(?), leucovorin, methotrexate(?), nafcillin, piperacillin/tazobactam

            IV Compatibilities

            Solution: D5W, LR, NS

            Syringe: atropine, bleomycin, butorphanol, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, dimenhydrinate, diphenhydramine, doxorubicin, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, midazolam, mitomycin, morphine sulfate, nalbuphine, papaveretum, pentazocine, perphenzine, prochlorperazine, promazine, promethazine, scopolamine, vinblastine, vincristine

            Y-site: alatrofloxacin, amifostine, azithromycin, aztreonam, bivalirudin, bleomycin, cisatracurium, cladribine, cisplatin, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposomal, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gatifloxacin, gemcitabine, granisetron, Hextend, hydrocortisone sodium succinate, idarubicin, linezolid, melphalan, meperidine, metoclopramide, mitomycin, ondansetron, paclitaxel, potassium chloride, propofol, remifentanil, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine, vitamin B/C

            IV/IM Administration

            Administered IM or slow IV (2-5 min)

            IV infusion has been used in high-risk pts

            Storage

            Controlled room temperature

            Protect from light

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            droperidol injection
            -
            2.5 mg/mL vial
            droperidol injection
            -
            2.5 mg/mL solution

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            droperidol injection

            NO MONOGRAPH AVAILABLE AT THIS TIME

            USES: Consult your pharmacist.

            HOW TO USE: Consult your pharmacist.

            SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Consult your pharmacist.

            DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: No monograph available at this time.

            MISSED DOSE: Consult your pharmacist.

            STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.